Scott Lonning

Dr. Lonning has over 16 years drug discovery and development experience. During his tenure at Genzyme, and later Sanofi; he led diverse programs in immunotherapy, pathologic fibrosis, and oncology and served as the Oncology Research Area Head where he was responsible for the research and early development of a portfolio of small molecule and biologic therapeutic candidates. He successfully advanced Genzyme’s first antibody program, an anti-TGFb antagonist, into multiple early clinical studies for idiopathic pulmonary fibrosis, focal segmental sclerosis, renal cell carcinoma and malignant melanoma.

More recently, Dr. Lonning served as Vice President, Target Discovery and Validation at Cell Signaling Technology where he managed a multi-disciplinary team devoted to the development of a portfolio of oncology targets and therapeutic antibody candidates for internal development, out-licensing, and co-development activities. He has co-authored over 40 scientific publications, has been named co-inventor on multiple patents, and has been invited to speak at scientific meetings around the world. He received his DVM from the University of California, Davis and comparative anatomic pathology training and PhD from Washington State University.